Evidence map›Paper›PMID 34919849›Full record

ArticleThe Lancet. Global health2022

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination.

Karina Soboleva, Nirmal Kumar Shankar, Madhavi Yadavalli, Cátia Ferreira, Nadia Foskett, Kert Putsepp, Lisa Beth Ferstenberg, Magnus Nord, Hugo Gomes da Silva, Prakash Bhuyan

Abstract readLetter
In one paragraph

Article in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia in middle-income countries.International journal of stroke : official journal of the International Stroke Society · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Viral vector vaccines.Current opinion in immunology · 2022
    Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karina SobolevaClinical Development, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.
Nirmal Kumar ShankarPatient Safety, Chief Medical Office, R&D, AstraZeneca India, Bangalore, India.
Madhavi YadavalliPatient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD, USA.
Cátia FerreiraBioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Nadia FoskettBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Kert PutseppBioPharmaceuticals, AstraZeneca, Gaithersburg, MD, USA.
Lisa Beth FerstenbergPatient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD, USA.
Magnus NordPatient Safety, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden.
Hugo Gomes da SilvaBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Prakash BhuyanClinical Development, Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Electronic address: prakash.bhuyan@astrazeneca.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ChAdOx1 nCoV-19COVID-19HumansThrombocytopeniaThrombosisVaccinationChAdOx1 nCoV-19

Identifiers

PMID34919849
PMCPMC8670752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.